COPD World News - 2018

COPD World News - Week of June 24, 2018

Effects of exercise training on cognition in COPD

Toronto, ON – As exercise may mitigate cognitive decline in individuals with chronic obstructive pulmonary disease (COPD), its effect has been evaluated in a number of clinical trials. The objective of the present systematic review was to describe the impact of exercise training on cognition in COPD. Electronic searches of four databases were performed from inception until March 24, 2015 and last updated 23rd October 2017. Included studies reported on at least one cognitive outcome before and after a formal exercise-training program in individuals with COPD. Two reviewers independently rated study quality using the Downs and Black checklist. The protocol was registered on PROSPERO (CRD42015017884). Seven articles, representing six exercise interventions in 293 individuals with COPD (55% males, mean age 67 ± 2 year) were included. Although each study documented a significant pre-post training improvement in at least one cognitive domain, the heterogeneity in study design, exercise intervention and cognitive outcome measures among studies precluded a meta-analysis. The only randomized controlled trial available reported an improvement on a letter verbal fluency task in the exercise group only. The researchers concluded that exercise training may positively impact cognition in COPD patients, but current evidence is limited by the heterogeneity of study design, exercise intervention and cognitive outcome measures. Future studies should emphasize comprehensive reporting of intervention parameters, including program length, type(s) of exercise, and duration of individual sessions, in order to facilitate applied insights to inform replication and/or program development. Lead authors of the study are Laura Desveaux, Samantha L. Harrison, Jean-François Gagnon, Roger S. Goldstein and Dina Brooks

For more information:

COPD World News - Week of June 17, 2018

End of life strategies among patients with advanced COPD 

Toronto, ON - The burden of advanced COPD is high globally; however, little is known about how often end of life strategies are used by this population. Researchers sought to describe trends in the use of end of life care strategies by people with advanced COPD in Ontario, Canada. A population-based repeated cross-sectional study examining end of life care strategies in individuals with advanced COPD was conducted. Annual proportions of individuals who received formal palliative care, long-term oxygen therapy or opioids from 2004 to 2014 were determined. Results were age- and sex- standardized as well as stratified by age, sex, socioeconomic status, urban/rural residence and immigrant status. There were 151,912 persons with advanced COPD in Ontario between 2004 and 2014. Use of formal palliative care services increased 1% per year from 5.3% in 2004 to 14.3% in 2014 (p value for trend <0.001), while use of long-term oxygen therapy increased 1.1% per year from 26.4% in 2004 to 35.3% in 2013 (p value for trend <0.001). The use of opioids was relatively stable (40.0% in 2004 and 41.8% in 2014, p value for trend=0.08). Younger individuals were less likely to use formal palliative care services and long-term oxygen therapy. Males were less likely than females to receive long-term oxygen therapy and opioids. Researchers concluded that the proportion of people with advanced COPD using end of life strategies, although increasing, remains low. Efforts should focus on increasing access to such strategies as well as educating patients and providers of their benefits. Lead authors of the study were: Gershon AS, Maclagan LC, Luo J, To T, Kendzerska T, Stanbrook MB, Bourbeau J, Etches J, Aaron SD. The study was published in the Am J Respir Crit Care Med. 2018; Jun 11

For more information:

COPD World News - Week of June 10, 2018

Study looks at hospitalizations due to exacerbations of COPD  

Barcelona, Spain - Patients with Chronic Obstructive Pulmonary Disease (COPD) may suffer episodes of exacerbation (ECOPD) that require hospitalization and worsen their health status, and prognosis. The researchers in this study hypothesized that a detailed interrogation of health-care “big data” databases can provide valuable information to better understand the risk factors and outcomes of these episodes. They investigated four databases of the Catalan health-care system (>8,000,000 registries) to identify patients hospitalized because of ECOPD for the first time (index event) between 2010 and 2012. Analysis was carried forward since the index event until the end of 2014 or the death of the patient. The two years that preceded the index event were also investigated. We identified 17,555 patients, (≥50 years of age) hospitalized because of ECOPD (ICD9 v.9 codes at discharge) for the first time between 2010 and 2012. In this population the researchers observed that: (1) 23% of patients die within a year after being discharged from their first ECOPD hospitalization; (2) in the remaining patients, all-cause mortality was related to the number of re-hospitalizations, particularly with early (<30 days) readmissions; (3) despite this being a ‘respiratory’ cohort, prescription and dispensation of drugs for cardiovascular diseases was higher than for obstructive airway diseases; and, finally, (4) lower winter ambient temperatures are associated with hospital admissions for ECOPD particularly in early re-admitters. They concluded that overall these results indicate under appreciation of the burden of COPD in patients hospitalized for the first time because ECOPD.

COPD World News - Week of June 3, 2018

1-Hour Exercise, 3 Times a Week Boosts Cognition in Older Adults  

Miami, FL - Exercising for 52 hours over a 6-month period may be an optimal dose for cognitive improvement in older adults, a systematic review of 98 randomized clinical trials suggested. Interventions that averaged 52 hours over a span of 6 months -- averaging about an hour, 3 times a week -- were linked to specific cognitive improvements in adults with and without cognitive impairment, reported Joyce Gomes-Osman, PT, PhD, of the University of Miami Miller School of Medicine, and colleagues in Neurology: Clinical Practice. "The constructs of cognition that were most amenable to exercise were processing speed and executive function," Gomes-Osman said. "This is an encouraging result because those two constructs are among the first that start to go with the aging process. "This is evidence that you can actually turn back the clock of aging in your brain by adopting a regular exercise regimen." Interestingly, statistical associations did not hold for memory improvement, noted Art Kramer, PhD, of Northeastern University in Boston, who was not involved in the study. "Despite the fact that animal studies have found robust memory benefits from exercise, memory benefits were not consistently observed in the human studies that were reviewed." Gomes-Osman's group searched medical databases in December 2016 for randomized controlled trials that tested the effect of exercise on cognition. After a review of 4,612 relevant studies, they included 98 trials with a total of 11,061 participants in their review. Participants had an average age of 73 and 67.58% were female. Of the total sample, 59.41% of participants were classified as older healthy adults, 25.74% had mild cognitive impairment (MCI), and 14.85% had dementia. The clinical trials assessed exercises that included walking, biking, dancing, strength training, tai chi, and yoga over spans from 4 weeks to 1 year. Most participants (58.2%) did not exercise regularly before enrolling in a study. Most studies used either high (37.8%) or medium intensity (36.7%) exercise. Aerobic exercise, strength training, mind-body exercises like yoga and tai-chi, and combinations of exercises all were linked to improved cognitive skills in both healthy individuals and those with MCI. Only the total length of time over a 6-month period was linked to improved cognitive skills, not weekly exercise minutes. "Although half of the exercise in the studies we assessed was in support of aerobic exercise, it doesn't mean that aerobic exercise necessarily was more effective," said Gomes-Osman. "It just means that more trials have actually studied aerobic exercise." Within aerobic exercise interventions, the most common exercise was walking, Gomes-Osman noted. "It's encouraging to know that you don't need to be running. If you start walking, you're going to get benefit. But this is not window-shopping; this is walking. It's physical exercise, not just physical activity." Since most participants did not exercise regularly before joining a trial, this data also "strongly supports that decreasing sedentary behavior is something associated with brain health," Gomes-Osman said. The effect of exercise on overall cognition is not clear because so few studies have assessed this, she added. And it's possible that future trials -- ones that compare different types of exercise or evaluate exercise in both physically fit and sedentary people -- may show different results. Nonetheless, some cognitive benefit is clear. "I believe in giving people knowledge about outcomes," Gomes-Osman said. "If you tell people to be active, they may be less interested overall than if you say 'You can do this, this, this, or this, and you need to keep it up a couple times a week for about 6 months, and then you should get a benefit.' I think that's a better sell for patients."

For more information:

COPD World News - Week of May 27, 2018

COPD: No 'Obesity Paradox' for BMI >40  

San Diego, CA The apparent "obesity paradox" in chronic obstructive pulmonary disease (COPD) is a head-scratcher for physicians: Studies suggest that COPD patients who are overweight and obese have an advantage in terms of both mortality and morbidity. Now, however, a new study finds that COPD patients who are extremely overweight -- i.e., those with a body mass index (BMI) above 40 -- do not gain this benefit. "Our results, combined with the work of others, suggest that BMI is an important factor physicians should consider when evaluating mortality risk in patients with COPD," said Emily Brigham, MD, MHS, of Johns Hopkins University School of Medicine in Baltimore, who presented the findings at the annual meeting of the American Thoracic Society. Among the previous data showing that being overweight bestows a survival advantage on COPD patients, she noted, is a 2018 study by Francesco Spelta et al, which found that the effect "is more evident for subjects with severe bronchial obstruction -- i.e., a lower FEV1 -- while in mild-moderate conditions, the weight-related mortality shows a behavior similar to that observed in the general population." Brigham explained. Today that agreement is lacking on whether the obesity paradox is directly related to excess fat. For example, if that was the case, a 2014 study suggested, "clinicians may be tempted to recommend weight gain to their patients." In fact, those authors said, other factors may be more important than weight itself: "Overweight/obese patients tended to have better preserved lung function, muscle mass, and exercise capacity -- all important predictors of mortality in this disease." For the study by Brigham and colleagues, the team examined data from the SUMMIT trial, a double-blind, randomized controlled study that examined the use of fluticasone furoate and vilanterol in adults with moderate COPD and cardiac risk. A total of 16,485 adults from 43 nations were included, all with histories of smoking at least 10 packs a day. "As expected, the majority of mortality was attributable to cardiovascular causes," Brigham said. "This held true in all BMI categories." The study found that underweight patients (i.e., with a BMI < 20) had a higher mortality rate compared with those of normal weight (BMI 20-25) at HR 1.31, 95% CI, 1.04-1.64. Those with with BMI > 40 also had a mortality disadvantage (HR 1.36, 95% CI, 1.00-1.86). Compared with in the normal weight group, mortality was lower in the overweight group (BMI 25 to 30: HR 0.62, 95% CI, 0.52-0.73) and the two obese groups (BMI 30-35: HR 0.75, 95% CI, 0.62-0.90; and BMI 35-40: HR 0.85, 95% CI, 0.66-1.10). Why might the obesity paradox fade out at higher BMIs? "Higher BMI is associated with a higher prevalence of a number of diseases that contribute to mortality, including metabolic and cardiovascular diseases," Brigham said. "We also know that at the extremes of obesity, lung function is reduced -- something that is particularly consequential in patients with COPD whose lung function is already compromised. It is reasonable to expect that at some threshold the positive effects of BMI in this population will be overwhelmed by the negative health consequences of obesity, as we see here." She cautioned, however, that the study does not prove causality: "Confounding of the relationships we see may still exist. For example, a large number of the participants with low BMI were from Asia, and we couldn't completely account for regional differences that may affect the relationship between BMI and outcomes." Even so, she said, the study has implications for practice. "If I have a patient with moderate COPD in my clinic and known cardiovascular disease or risk factors, I have increased concern about his or her mortality risk when he or she is underweight or has a BMI greater than 40. "Regardless of the underlying lung disease, discussing nutrition and physical activity is an important part of caring for our patients, and sharing the results of studies such as this can provide motivation for change."

For more information:

COPD World News - Week of May 20, 2018

Step-Down therapy in severe COPD OK for some   

San Diego, CA - Patients with chronic obstructive pulmonary disease (COPD) without a high eosinophil burden and who were doing well on triple therapy had no increase in exacerbations when switched to the dual-bronchodilator therapy indacaterol/glycopyrronium (Ultibro Breezhaler) in the randomized, double blind, triple-dummy SUNSET trial reported here. Patients in the study with consistent blood eosinophil counts of 300 μl or above, however, showed significant declines in lung function and increased risk for exacerbation on the fixed-dose dual therapy, suggesting that they are more likely to benefit from continued triple therapy. The study is the first to evaluate the efficacy and safety of direct de-escalation from long-term triple therapy to the once-daily long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) treatment in patients with moderate-to-severe COPD who do not have frequent exacerbations. Findings from the study, funded by Breezhaler's manufacturer, Novartis, were reported this week at ATS 2018, the annual international meeting of the American Thoracic Society, and published simultaneously in the American Journal of Respiratory and Critical Care Medicine. Current GOLD (Global Initiative for Obstructive Lung Disease) recommendations call for the addition of inhaled corticosteroids (ICS) to LABA/LAMA as triple therapy in high-risk patients experiencing exacerbations on LABA/LAMA treatment alone. But the long-term use of ICS has been linked to numerous adverse events, including pneumonia, mycobacterial infection, diabetes onset and progression, and osteoporosis. The aim of the study, led by Kenneth Chapman, PhD, of the University of Toronto, was to identify patients who might be able to safely step-down treatment to a LABA/LAMA without ICS. The WISDOM trial showed that in patients with severe to very severe COPD susceptible to exacerbations, the risk of moderate or severe exacerbations was similar in patients who followed a stepwise ICS withdrawal compared with those who continued with ICS. No prior studies evaluating ICS withdrawal in patients on long-term triple therapy in the absence of frequent exacerbations, however, have been reported.

For more information:

COPD World News - Week of May 13, 2018

Nova Scotia approves high-dose flu vaccine in long-term care facilities

Halifax, NS – Great news for thousands of Nova Scotians living in long-term care facilities who will have access to a new flu vaccine this fall. The vaccine will provide greater protection for seniors and is expected to reduce hospital stays. The high-dose vaccine is formulated specifically for elderly adults with chronic, complex health conditions. It is four times the strength of the standard vaccine and helps boost immune response. It is significantly more effective than the standard vaccine for the frail elderly. “Nova Scotians living in long-term care facilities have the highest rates of severe illness and hospitalizations from influenza,” said Health and Wellness Minister Randy Delorey. “By making the high-dose flu vaccine available in our long-term care facilities this year, we’re helping protect those most atrisk.” Government will purchase more than 7,000 doses of the vaccine for adults living in long-term and residential care facilities across Nova Scotia. Evidence suggests immunizing all long-term care residents with the vaccine could result in about 100 fewer hospital stays. Adults 65 and older represent only 15 per cent of the Canadian population, but experience 67 per cent of influenza-related complications and 88 per cent of influenza-related deaths. The H3N2 strain, which is currently the predominant circulating Influenza A strain in Canada, produces particularly severe illness in the elderly. “Because the immune system declines as we age, older adults are more susceptible to influenza even when they are vaccinated – and this is especially true of individuals in long-term care,” said Dr. Robert Strang, chief medical officer of health. “For the general population, the standard vaccine provides adequate protection against the flu. But evidence shows that for elderly people with multiple chronic conditions, the high-dose vaccine yields better protection and fewer complications from the flu.” Vaccines for the upcoming flu season will be available in the fall. The standard flu vaccine is available to all Nova Scotians free of charge through their care providers, community pharmacies and public health and employer clinics.

Study finds inhaled blood thinner can help ease COPD 

Portsmouth, UK - A blood thinner normally injected into patients at risk of clots can help ease chronic lung diseases when it’s inhaled. Researchers at the University of Portsmouth found that heparin, a drug that has been around for more than 100 years, significantly improves lung function and breathing in patients with chronic obstructive pulmonary disease (COPD). COPD, which affects around a million people, is an umbrella term for lung diseases such as emphysema and chronic bronchitis; patients find it difficult to get air in and out of the lungs, partly because the airways become inflamed and narrow. UK scientists have discovered that turning the drug heparin into an aerosol, which can be inhaled through a face mask, can boost patients’ lung function. The main cause is smoking, but pollution and genetics have also been implicated. Over time, the walls of the airways thicken and mucus is produced, which worsens symptoms. One of the first signs is a cough, but it eventually causes extreme breathlessness and wheezing. Treatment involves medication, often through nebulizers, to reduce inflammation and allows more oxygen into the lungs, or exercise programs to bolster lung capacity. Now UK scientists have discovered that turning the drug heparin into an aerosol, which can be inhaled through a face mask, can boost patients’ lung function. Heparin is normally used in injection form for patients at risk of a blood clot, such as those who’ve recently had surgery or have a faulty heart rhythm. The drug binds to a protein in the blood which stops it clotting. But research has found the structure of the heparin molecule means it has potential roles in other treatments, according to Janis Shute, a professor of respiratory pharmacology, who led the new study at the University of Portsmouth. For example, a laboratory study found that heparin has mucus-thinning properties, making it potentially useful for helping clear a patient’s airways. Heparin is normally used in injection form for patients at risk of a blood clot, such as those who’ve recently had surgery or have a faulty heart rhythm. To test this, the Portsmouth scientists reformulated heparin into fine particles that could be inhaled as an aerosol and put these particles into a device connected to a mask which contained a propellant gas that would force it into the lungs. In a pilot study involving 40 COPD patients, inhaled heparin was found to boost lung function by at least 10 per cent within days of treatment starting, and this made it significantly easier for patients to breathe in more air, according to a report in the European Respiratory Journal. The patients had the treatment twice a day for three weeks, with each session lasting 15 minutes. Professor Shute said: ‘Heparin thins mucus in the airways, which allows patients to clear their airways more easily, but it also acts as an anti-inflammatory.’ It’s not clear yet whether COPD patients will need to inhale the drug every day, or just when symptoms are particularly bad. The researchers are now planning a trial to see if heparin inhaled daily can benefit patients with cystic fibrosis, the genetic disorder that causes lungs to become seriously congested with mucus. ‘Nothing we have at the moment does anything to the mucus levels, and it’s a huge problem,’ says Jorgen Vestbo, a professor of respiratory medicine at University Hospital South Manchester NHS Foundation Trust.

For more information:

COPD World News - Week of May 6, 2018

Tai Chi and pulmonary rehab compared for treatment-naive COPD patients   

Guangzhou, China – In COPD, functional status is improved by pulmonary rehabilitation (PR) but requires specific facilities was the basic assumption of researchers here. Tai Chi, which combines psychological treatment and physical exercise and requires no special equipment, is widely practiced in China and is becoming increasingly popular in the rest of the world. The researchers hypothesized that Tai Chi is equivalent (ie, difference less than ±4 St. George’s Respiratory Questionnaire [SGRQ] points) to PR. A total of 120 patients (mean FEV 43.6% predicted) bronchodilator-naive patients were studied. Two weeks after starting indacaterol 150 μg once daily, they randomly received either standard pulmonary rehab thrice weekly or group Tai Chi five times weekly, for 12 weeks. The primary end point was change in SGRQ prior to and following the exercise intervention; measurements were also made 12 weeks after the end of the intervention. The between-group difference for SGRQ at the end of the exercise interventions was –0.48 (95% CI PR vs Tai Chi, –3.6 to 2.6; P = .76), excluding a difference exceeding the minimal clinically important difference. Twelve weeks later, the between-group difference for SGRQ was 4.5 (95% CI, 1.9 to 7.0; P < .001), favoring Tai Chi. Similar trends were observed for 6-min walk distance; no change in FEV1 was observed. The researchers concluded that Tai Chi is equivalent to pulmonary rehab for improving SGRQ in COPD. Twelve weeks after exercise cessation, a clinically significant difference in SGRQ emerged favoring Tai Chi, therefore they stated that Tai Chi is an appropriate substitute for PR. Lead authors of the published study are Michael I. Polkey, PhD of London and Zhi-Hui Qiu, MSc of Guangzhou China. The study was recently released in the journal CHEST.
For more information:

COPD World News - Week of April 29, 2018

Antibiotic treatment and the outcomes of exacerbations of asthma and COPD  

Liverpool, UK – Asthma and chronic obstructive pulmonary disease (COPD) cause significant morbidity and mortality worldwide, primarily through exacerbations. Exacerbations are often treated with antibiotics but their optimal course duration is uncertain. Reducing antibiotic duration may influence antimicrobial resistance but risks treatment failure. The objective of this article is to review published literature to investigate whether shorter antibiotic therapy duration affects clinical outcomes in the treatment of asthma and COPD exacerbations. We systematically searched electronic databases (MEDLINE, EMBASE, CINAHL, World Health Organisation International Clinical Trial Registry Platform, the Cochrane library, and ISRCTN) with no language, location, or time restrictions. We retrieved observational and controlled trials comparing different durations of the same oral antibiotic therapy in the treatment of acute exacerbations of asthma or COPD in adults. We found no applicable studies for asthma exacerbations. We included 10 randomized, placebo-controlled trials for COPD patients, all from high-income countries. The commonest studied antibiotic class was fluoroquinolones. Antibiotic courses shorter than 6 days were associated with significantly fewer overall adverse events (risk ratio (RR): 0.84, 95% confidence interval (CI): 0.75–0.93, p = 0.001) when compared with those of 7 or more days. There was no statistically significant difference for clinical success or bacteriological eradication in sputum (RR: 1.00, 95% CI: 0.88–1.13 and RR: 1.06, 95% CI: 0.79–1.44, respectively). Shorter durations of antibiotics for COPD exacerbations do not seem to confer a higher risk of treatment failure but are associated with fewer adverse events. This is in keeping with previous studies in community acquired pneumonia, but studies were heterogeneous and differed from usual clinical practice. Further observational and prospective work is needed to explore the significance of antibiotic duration in the treatment of asthma and COPD exacerbations.

For more information:

COPD World News - Week of April 22, 2018

Trial Backs Triple-Drug Inhaler for COPD  

Chapel Hill, NC - Treatment with the first approved once-daily, single inhaler triple therapy for COPD resulted in a significantly lower rate of exacerbations, as well as better lung function and quality of life compared to dual therapy in patients with a history of exacerbations, researchers rep orted.Results from the huge IMPACT trial supported an extra benefit from the GlaxoSmithKline and Innoviva product Trelegy Ellipta -- containing an inhaled corticosteroid, a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA) -- versus two of GlaxoSmithKline's two-drug inhalers.The trial, reported in the New England Journal of Medicine with GlaxoSmithKline researcher David Lipson, MD, as lead author, showed statistically significant and clinically relevant reductions in COPD exacerbations for the three-drug product. It was noted that that the study design criticized by journal editor. Pulmonary disease specialist James Donohue, MD, of the University of North Carolina School of Medicine, Chapel Hill, said despite several limitations to the study, the robust difference in outcomes between the triple and dual therapy groups was impressive. "The triple treatment was compared to two really good dual combination therapies and it beat both easily," he said. "That was something of a surprise." Donahue, who was not involved with the study, noted that the findings challenge the common belief that treatment with an inhaled steroid adds little value to LAMA-LABA dual therapy. "The idea is that the LAMA-LABA combination is so effective that patients don't need steroids, which have side effects," he said. "The new findings kind of turn things upside down." At the same time, however, an editorial co-written by NEJM's editor-in-chief said the study's design called the results into question. Trelegy Ellipta became the first single inhaler, dry powder treatment for COPD to combine a steroid (fluticasone furoate), LAMA (umeclidinium), and LABA (vilanterol) when it was approved by the FDA last Septe mber. All patients recruited for the IMPACT trial had symptomatic COPD and a history of exacerbations occurring within a year of enrollment. Triple therapy is recommended in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) treatment guidelines for patients with clinically significant symptoms despite treatment with an inhaled steroid and a LABA or LABA-LAMA combined treatment who have an elevated risk for exacerbations. Lipson and colleagues noted that some controversy remains regarding the relative benefits of triple therapy compared to dual therapy in this patient population.
For more information:

COPD World News - Week of April 15, 2018

Observing dyspnoea in others elicits dyspnoea 

Leuven, Belgium - According to a study recently published in the European Respiratory Journal (Vol 51, issue 4) dyspnea (breathlessness) is usually caused by diagnosable cardiorespiratory mechanisms. However, frequently dyspnoea relates only weakly or not at all to cardiorespiratory functioning, suggesting that additional neuro-psychosocial processes contribute to its experience. The researchers tested whether the mere observation of dyspnoea in others constitutes such a process and would elicit dyspnoea, negative affect and increased brain responses in the observer. In three studies, series of pictures and videos were presented, which either depicted persons suffering from dyspnoea or non-dyspnoeic control stimuli. Self-reports of dyspnoea and affective state were obtained in all studies. Additionally, respiratory variables and brain responses during picture viewing (late positive potentials in electroencephalograms) were measured in one study. In all studies, dyspnoea-related pictures and videos elicited mild-to-moderate dyspnoea and increased negative affect compared to control stimuli. This was paralleled by increased late positive potentials for dyspnoea-related pictures while respiratory variables did not change. Moreover, increased dyspnoea correlated modestly with higher levels of empathy in observers. The present results demonstrate that observing dyspnoea in others elicits mild-to-moderate dyspnoea, negative affect, and increased brain responses in the absence of respiratory changes. This vicarious dyspnoea has clinical relevance, as it might increase suffering in the family and medical caregivers of dyspnoeic patients.

For more information:

COPD World News - Week of April 8, 2018

Antibiotic treatment and the outcomes of exacerbations of COPD   

Liverpool, UK – Chronic obstructive pulmonary disease causes significant morbidity and mortality worldwide, primarily through exacerbations. Exacerbations are often treated with antibiotics but their optimal course duration is uncertain. Reducing antibiotic duration may influence antimicrobial resistance but risks treatment failure. The objective of this article is to review published literature to investigate whether shorter antibiotic therapy duration affects clinical outcomes in the treatment of asthma and COPD exacerbations. The researchers systematically searched electronic databases (MEDLINE, EMBASE, CINAHL, World Health Organisation International Clinical Trial Registry Platform, the Cochrane library, and ISRCTN) with no language, location, or time restrictions. They retrieved observational and controlled trials comparing different durations of the same oral antibiotic therapy in the treatment of acute exacerbations of asthma or COPD in adults. They found no applicable studies for asthma exacerbations. The researchers included 10 randomized, placebo-controlled trials for COPD patients, all from high-income countries. The commonest studied antibiotic class was fluoroquinolones. Antibiotic courses shorter than 6 days were associated with significantly fewer overall adverse events (risk ratio (RR): 0.84, 95% confidence interval (CI): 0.75–0.93, p = 0.001) when compared with those of 7 or more days. There was no statistically significant difference for clinical success or bacteriological eradication in sputum (RR: 1.00, 95% CI: 0.88–1.13 and RR: 1.06, 95% CI: 0.79–1.44, respectively). Shorter durations of antibiotics for COPD exacerbations do not seem to confer a higher risk of treatment failure but are associated with fewer adverse events. This is in keeping with previous studies in community acquired pneumonia, but studies were heterogeneous and differed from usual clinical practice. Further observational and prospective work is needed to explore the significance of antibiotic duration in the treatment of asthma and COPD exacerbations.  

For more information:

COPD World News - Week of April 1, 2018

High COPD assessment test (CAT) score may predict anxiety  

Perth, Australia - The prevalence of anxiety in patients with COPD is estimated to be 55%. And, the anxiety is associated with worse disease control. Researchers here questioned whether early recognition and institution of treatment of this comorbidity could significantly improve patient’s quality of life. Recently, a questionnaire called the COPD assessment test (CAT) has been incorporated into the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for the management of COPD, and a higher score is associated with increased COPD symptoms. Considering the regular use of CAT, it was evaluated whether this tool can also be used to identify anxiety. The CAT score was correlated with the Hospital Anxiety and Depression Scale (HADS) to determine the level at which CAT may predict anxiety.Materials and methods. This particular study was approved by the Human Research Ethics Committee of the Royal Perth Hospital (HREC study 2012/055), with a waiver given for patient consent. All patient data remained confidential. Clinical data were collected from 100 patients with confirmed COPD, who attended the COPD outreach clinic, of whom 78 patients completed spirometry. COPD severity was graded according to the GOLD criteria, and the CAT and HADS scores were collected on 2 consecutive consultations separated by 6 months with a 100% completion rate. The severity of the cohort was classified as GOLD 1 (2 patients), GOLD 2 (29 patients), GOLD 3 (39 patients) and GOLD 4 (8 patients). A total of 45 patients had clinically significant anxiety on the first visit and 38 patients on the second visit as per HADS. The prevalence of anxiety in COPD GOLD 1 is 0%, GOLD 2 is 45% (13), GOLD 3 is 56% (22) and GOLD 4 is 38% (3) in visit 1. Data from the second visit were similar, apart from the decreased prevalence in GOLD 3 (13, 43%) and the increased prevalence in GOLD 4 (6, 67%). This study suggests that anxiety must be specifically investigated in COPD patients, especially with a CAT score of ≥20. Further analysis with a larger sample size should further evaluate the value of CAT score correlation with anxiety in COPD patients.

For more information:

COPD World News - Week of March 25, 2018

No decrease in outpatient antibiotic prescribing in over 3 years  

Washington, DC - Outpatient antibiotic prescribing in the United States remained unchanged over a 3-year period despite efforts to limit inappropriate antimicrobial use, according to researchers. The data, w hich include only prescriptions for insured patients and do not show use of antibiotics by the uninsured, show that further efforts are needed to control antibiotic use in the context of resistance, they wrote in Infection “The findings of this study are concerning but more than anything, they give us important insight into the ongoing challenges of getting health care providers to change their prescribing habits to help prevent antibiotic resistance,” Keith Kaye, MD, MPH, president of the Society for Healthcare Epidemiology of America, told Infectious Disease News. “While the resources and investments made to identify and raise awareness regarding overuse of antibiotics are important, they are not enough.” To assess levels of prescribing in the outpatient setting, researcher Michael J. Durkin, MD, MPH, an assistant professor of medicine at the Washington University School of Medicine, and colleagues conducted a retrospective study of antibiotic prescriptions made between Jan. 1, 2013, and Dec. 31, 2015, using an Express Scripts Holding company database of insured members. The researchers found about 98 million outpatient prescriptions filled by 39 million patients. The most commonly prescribed drugs were amoxicillin, amoxicillin/clavulanate, azithromycin, cephalexin and ciprofloxacin. They also found that rates of prescriptions varied significantly by season because antibiotics were much more likely to be prescribed in February than they were to be prescribed in September, with a peak-to-trough ratio (PTTR) of 1.42 (95% CI, 1.39-1.61). Similarly, azithromycin (PTTR = 2.46; 95% CI, 2.44-3.47), amoxicillin (PTTR = 1.52; 95% CI, 1.42-1.89) and amoxicillin/clavulanate (PTTR = 1.78; 95% CI, 1.68-2.29) had peaks and troughs in February and August. The common use of those three drugs in winter could be partly appropriate, the researchers said, because diseases like pneumonia are more prevalent then. Likewise, peak use of cephalexin and ciprofloxacin in the summer, when urinary tract infections and skin and soft tissue infections are more common, could be partly appropriate. However, Durkin and colleagues also cited literature suggesting that wintertime prescription increases could be due to inappropriate antibiotic use for viral infections. Even so, the researchers said current efforts to control antibiotic use are falling short. Durkin suggested that health care systems abide by the CDC Core Elements of Outpatient Antibiotic Stewardship, meant to educate caregivers on the topic. The Core Elements also include recommendations for accountability in prescribing, enacting policies to improve antibiotic prescribing, and tracking and reporting antibiotic unitization to providers. Even measures as simple as having posters promoting stewardship can bring about improvement, the researchers noted. Although interventions and their effectiveness vary, Durkin and colleagues said further research on antibiotic prescribing is needed, along with further efforts at convincing providers to be better stewards.“Additional work is needed to better link antibiotic prescriptions to indications to better quantify and trend inappropriate antibiotic prescribing practices,” they wrote. “However, in our opinion, additional interventions, beyond guidelines and educational materials, will be required to substantially improve antibiotic prescribing at a national level

For more information:

COPD World News - Week of March 18, 2018

Ontario expands OHIP+ to include seniors

Toronto, ON - Premier Kathleen Wynne announced Ontario's plan to make prescription drugs free for people 65 and over, ensuring millions of people can afford the care they need during this period of economic change and uncertainty. Through an expansion of OHIP+, more than 4,400 prescription drugs will be available free of charge to everyone 65 and over. The Premier was joined by Minister of Health and Long-Term Care Helena Jaczek and Minister of Seniors Affairs Dipika Damerla at the Leaside Curling Club to lay out the government's plan to expand OHIP+ and make life more affordable for 2.6 million seniors and their families. Starting August 1, 2019, anyone aged 65 or older will no longer have to pay a deductible or co-payment and would be able to present their eligible prescription and OHIP number at any Ontario pharmacy and receive their medication for free. On January 1, 2018, Ontario introduced OHIP+ Children and Youth Pharmacare, which made eligible prescription drugs free for everyone 24 and under and is the largest expansion of medicare in a generation. By expanding OHIP+ to seniors in Budget 2018, people 65 and over will now save an average of $240 every year. Prescription drugs covered by this program include medications for cholesterol, hypertension, thyroid conditions, diabetes and asthma. Today's announcement builds on steps taken to improve care and make life more affordable for seniors in Ontario. The announcement confirms the government’s promise to cover the costs of a high-dose flu vaccine beginning in time for the 2018 – 2019 flu season. Making prescription drugs free for people 65 and over is part of the government's plan to support care, create opportunity and make life more affordable during this period of rapid economic change. The plan includes a higher minimum wage and better working conditions, free tuition for hundreds of thousands of students, easier access to affordable child care, and free prescription drugs for everyone under 25 through the biggest expansion of medicare in a generation.

For more information:

COPD World News - Week of March 11, 2018

End-of-life care in a patients’ home can reduce the risk of dying in hospital   

Toronto, ON - Most Ontarians want to die at home, but despite this nearly 70 per cent die in hospitals or long-term care facilities. A new study from the Institute for Clinical Evaluative Sciences (ICES) shows end-of-life care like doctor house calls or in-home palliative care could reduce the chance of dying in hospital by about 50 per cent. Yet, fewer than 1 in 5 Ontarians receive doctor house calls or palliative home care in their last year of life “Our research has shown that end-of-life care in a patients’ home can dramatically reduce the risk of dying in hospital,” says Dr. Peter Tanuseputro, the lead author of the study, adjunct scientist at ICES, researcher at the Bruyère Research Institute and a staff physician at division of palliative care at The Ottawa Hospital Research Institute. The study is the largest of its kind to show the effect of doctor home visits on where people die. Using secure patient health records housed at ICES, the researchers looked at 264,755 Ontario decedents from April 1, 2010 to March 31, 2013 and found receiving doctor house calls for end-of-life care reduces the chance of dying in hospital by about 50 per cent and receiving palliative home care also reduces the chance of dying in hospital by about 50 per cent. “Most people would be able to die at home if they had the supports in place to make that happen. Unfortunately, in most areas across Canada, it’s quite arbitrary who gets palliative care in the home, depending on factors like if your family doctor does home visits, what neighborhood you live in, and what you’re dying of. Canada remains in the back of the pack in developed nations in terms of the percentage who die in hospital,” says Tanuseputro. The researchers found less than one in five Ontarians receive doctor house calls or palliative home care in their last year of life. “Our research points to the need for a structured palliative care strategy across the province to ensure people have a choice of dying in their homes, and not in hospitals, if they wish. As it stands now, who can access home palliative care really varies across Ontario,” adds Tanuseputro. About 38 per cent of physicians in Ontario deliver palliative care, and only a small minority of those doctors provides home visits. Only one in five palliative care encounters happen in patients’ homes. Tanuseputro points to other studies that his group has done that show patients with certain diagnoses, like cancer, and those who live in wealthier neighborhoods have a much higher chance of getting a home visit. “Associations between physician home visits for dying and place of death: a population-based retrospective cohort study” was published in the journal PLOS ONE.

For more information:

COPD World News - Week of March 4, 2018

New-found stem cell helps regenerate lung tissue after acute injury  

Philadelphia, PA - Researchers have identified a lung stem cell that repairs the organ's gas exchange compartment, according to a new study from the Perelman School of Medicine at the University of Pennsylvania. They isolated and characterized these progenitor cells from mouse and human lungs and demonstrated they are essential to repairing lung tissue damaged by severe influenza and other respiratory ailments. The research, led by Edward E. Morrisey, PhD, a professor of Cell and Developmental Biology, was published the journal Nature. Morrisey is also director of the Penn Center for Pulmonary Biology and scientific director of the Institute for Regenerative Medicine. The development of the lung, or pulmonary system, is an evolutionary adaption to life on land. Lungs are essential in most large animals for a terrestrial existence. Their complex structure, which is dictated in part by their integration with the cardiovascular system, makes them an interesting yet difficult organ to study from a regeneration medicine perspective. In addition, lung disease is one of the leading causes of death in the world, surpassed only by cardiovascular disease and cancer. "One of the most important places to better understand lung regeneration is in the alveoli, the tiny niches within the lung where oxygen is taken up by the blood and carbon dioxide is exhaled," Morrisey said. "To better understand these delicate structures, we have been mapping the different types of cells within the alveoli. Understanding cell-cell interactions should help us discover new players and molecular pathways to target for future therapies." The Nature study examined the epithelial cells that line the surfaces of lung gas-exchange alveoli for stem cell behavior that could restore normal respiratory function after severe injury caused by an influenza infection or in such diseases as chronic obstructive pulmonary disease (COPD). While some organs, such as the intestine, turn over the entire epithelial lining every five days through the activity of a resident stem-cell lineage, organs such as the lung exhibit very slow turnover and contain stem cells that are activated only upon injury to regenerate the damaged tissue. The team identified an alveolar epithelial progenitor (AEP) lineage which is embedded in a larger population of cells called alveolar type 2 cells, or AT2s. These cells generate pulmonary surfactant (a wetting agent), which keeps the lungs from collapsing upon every breath taken. "AEPs are a stable lineage in the lung and turn over very slowly, but expand rapidly after injury to regenerate the lining of the alveoli and restore gas exchange," said co-first author Will Zacharias, MD, PhD, a postdoctoral fellow in Morrisey's lab. David B. Frank, MD, PhD, a pediatric cardiologist at Children's Hospital of Philadelphia, is the other co-first author. AEPs exhibit their own distinct suite of genes and contain a unique epigenetic signature. The Morrisey lab used the genomic information gained from mouse AEPs to identify a conserved cell surface protein called TM4SF1 that can be used to isolated AEPs from the human lung. Using this ability to isolate mouse and human AEPs, the team then generated David B. Frank three-dimensional lung organoids. "From our organoid culture system, we were able to show that AEPs are an evolutionarily conserved alveolar progenitor that represents a new target for human lung regeneration strategies," Morrisey said. The team has access to more than 300 lungs through the lung transplant program headed by Edward Cantu, MD, an associate professor of Surgery. For their next study, the team aims to investigate influenza-damaged lung tissue as well as other lung disease models to determine where and when AEPs increase in response to acute lung injury or more chronic disease states. Given the severity of the current influenza season, these studies provide new insight into how the human lung regenerates and identifies novel genetic and epigenetic pathways important for lung regeneration. The team is now exploring which of these molecular pathways may promote AEP function in the mouse and human lung, including understanding whether drugs designed to activate Fgf signaling, one of the key pathways conserved in mouse and human AEPs, may promote lung regeneration. "We are very excited at this novel finding," said James P. Kiley, PhD, director of the Division of Lung Diseases at the National Heart, Lung, and Blood Institute, which supported the study. "Basic studies are fundamental stepping stones to advance our understanding of lung regeneration. Furthermore, the NHLBI support of investigators from basic to translational science helps promote collaborations that bring the field closer to regenerative strategies for both acute and chronic lung diseases."

For more information:

COPD World News - Week of February 25, 2018

Smoking rates in US remain at 15.5%   

Atlanta, GA - The U.S. Surgeon General has concluded that the burden of death and disease from tobacco use in the United States is overwhelmingly caused by cigarettes and other combusted tobacco products (1). Cigarettes are the most commonly used tobacco product among U.S. adults, and about 480,000 U.S. deaths per year are caused by cigarette smoking and secondhand smoke exposure (1). To assess progress toward the Healthy People 2020 target of reducing the proportion of U.S. adults aged ≥18 years who smoke cigarettes to ≤12.0% (objective TU-1.1),* CDC analyzed data from the 2016 National Health Interview Survey (NHIS). In 2016, the prevalence of current cigarette smoking among adults was 15.5%, which was a significant decline from 2005 (20.9%); however, no significant change has occurred since 2015 (15.1%). In 2016, the prevalence of cigarette smoking was higher among adults who were male, aged 25–64 years, American Indian/Alaska Native or multiracial, had a General Education Development (GED) certificate, lived below the federal poverty level, lived in the Midwest or South, were uninsured or insured through Medicaid, had a disability/limitation, were lesbian, gay, or bisexual (LGB), or had serious psychological distress. During 2005–2016, the percentage of ever smokers who quit smoking increased from 50.8% to 59.0%. Proven population-based interventions are critical to reducing the health and economic burden of smoking-related diseases among U.S. adults, particularly among sub-populations with the highest smoking prevalence. NHIS is an annual, nationally representative in-person survey of the non-institutionalized U.S. civilian population. The NHIS core questionnaire is administered to a randomly selected adult in the household (the sample adult). In 2016, the NHIS was administered to 33,028 adults aged ≥18 years; the response rate was 54.3%. Current cigarette smokers were respondents who reported having smoked ≥100 cigarettes during their lifetime and were smoking every day or some days at the time of interview. Former smokers were respondents who reported having smoked ≥100 cigarettes during their lifetime but were not smoking at the time of interview. The mean number of cigarettes smoked per day was calculated among daily smokers. Quit ratios were defined as the ratio of former smokers to ever smokers (i.e., persons who had smoked ≥100 cigarettes during their lifetime).

For more information:

COPD World News - Week of February 18, 2018

The influence of psychiatric disorders on lung cancer, COPD and TB    

Aarhus, Denmark - This Danish study evaluated the association between psychiatric comorbidity and the course of chronic obstructive pulmonary disease (COPD), lung cancer and tuberculosis (TB) of an entire nation. Data from the Danish National Patient Registry (1998–2009), material status, gender, educational level, comorbidities, age at diagnosis and death, medication, and causes of death were extracted from national databases. The researchers identified 71,874 patients with COPD and found 32,282 with a pre-index psychiatric comorbidity, 20,787 patients with lung cancer and found 8406 with a pre-index psychiatric comorbidity, and 3495 patients with TB and found 797 with a pre-index psychiatric morbidity. Within the three groups the researchers compared the patients with/without a pre-index psychiatric comorbidity. The researchers found a reduced survival in patients with COPD or TB and a pre-existing psychiatric comorbidity. For all three pulmonary diseases, they found significantly higher age (p < .001) at time of diagnosis, higher Deyo-Charlson Comorbidity Index and an overrepresentation of singles in patients with a psychiatric comorbidity. COPD and lung cancer patients with a psychiatric comorbidity were significantly overrepresented by women. Patients with COPD and a psychiatric comorbidity died most frequently of lung cancer (24%). Advancing age and Deyo-Charlson index were associated with a higher mortality rate whereas being a woman and married/co-habiting yielded a lower mortality rate for patients with a psychiatric comorbidity. The authors of the study concluded that to the best of their knowledge, this is the first epidemiological study investigating the influence of a psychiatric comorbidity on the course of COPD, lung cancer and TB at a national level. Their results emphasize the importance of detecting these major respiratory diseases in patients with psychiatric comorbidities and intensifying the treatment and follow up of these patients. Lead authors of the study is Melina Gade Sikjaer, Anders Lokke and Ole Hilberg of Aarhus University Hospital.

For more information:

COPD World News - Week of February 11, 2018

GSK voluntarily recalls Ventolin Diskus in Canada 

Mississauga, ON – On February 16th, GlaxoSmithKline Canada (GSK) announced that they are voluntarily recalling one lot (Lot 786G of VENTOLIN DISKUS 200mcg) in Canada. According to GSK they are taking this action after becoming aware of a manufacturing issue that may result in a small number of VENTOLIN DISKUS devices not delivering the full number of doses in the device. No adverse events have been reported as a result of this manufacturing issue. Their news release emphasized that patient safety remains their absolute priority and that they are taking this issue very seriously. GSK asks patients with VENTOLIN DISKUS to check the lot details on their device. The lot number is contained on the bottom of the VENTOLIN DISKUS cardboard package (4 characters after the word “lot”) or in the centre of the device (similarly 4 characters after the word “lot”). VENTOLIN DISKUS devices carrying the recalled lot number 786G should be returned to the local pharmacy where the device was purchased - for replacement. VENTOLIN metered dose inhalers, commonly referred to as “puffers” (tradename “VENTOLIN HFA”) are not affected by this issue and patients can continue to use as prescribed by their healthcare professional. GSK states that they have carried out a thorough investigation and the root cause of the issue has been corrected.

For more information:

Many smokers are not honest about quitting   

Kansas City, KA - Almost half (40%) of recently hospitalized smokers enrolled in smoking cessation trials fail biochemical verification of self-reported abstinence from smoking, according to a recent study published in the journal Addiction and summarized on-line by MDLinx. “Participants may feel pressure to say they have quit when they have not, so it is essential in studies to verify claims of quitting using an objective test such as cotinine to know true quit rates,” said lead author Taneisha Scheuermann, PhD, researcher, University of Kansas Cancer Center, Kansas City, KA. In the body, nicotine is converted into cotinine by the liver. Measuring cotinine via saliva sampling is a highly accurate measure of whether someone has smoked in the past few days. Dr. Scheuermann and fellow researchers conducted this study, therefore, to estimate the prevalence and possible predictors of failed biochemical verification of self-reported smoking abstinence in subjects enrolled in trials of hospital-initiated smoking cessation interventions. They compared characteristics in subjects who verified, and those who failed to verify, self-reported smoking cessation. They included 1,178 recently hospitalized smokers reporting tobacco abstinence for 6 months after randomization, who provided a saliva sample for verification, and who were enrolled in multi-site randomized clinical trials performed between 2010 and 2014 in hospitals throughout the US. Adequate saliva samples were returned by 822 subjects, who reported that they had quit smoking for the past 7 days. In all, 57.8% of subjects were verified as quitting when the 10 ng/mL cut-off was used and 60.6% were verified at the 15 ng/mL cut-off). Researchers found that the factors independently associated with verification at the 10 ng/mL cut-off included education beyond high school, continuous abstinence since hospitalization, mailed vs in-person sample and race. African American subjects were less likely to verify abstinence compared with white subjects. These findings were similar for verification at the 15 ng/mL cut-off, and verification rates did not differ by treatment group. Misreporting may have been even higher, as 18.6% of subjects who said they had quit smoking did not reply, despite multiple attempts and an offer of $50 to $100 for providing a sample. Yet Dr. Scheuermann noted that the most important tool in helping smokers quit is not a biological test, but rather, the patient-provider relationship. Providers must recognize how difficult overcoming an addiction can be. “Providers can create a non-judgmental, collaborative atmosphere that will help smokers better engage in the treatment process and discuss when they slip and smoke. They should tell patients that they know it’s hard to quit, and that they’re prepared to help patients change medications and sources of support until they get the right combination—the one that helps the patient quit,” she said. Still, if patients do not accurately report their tobacco habits, providers cannot provide the best care. “It’s hard to quit smoking. Slips and relapses are part of the normal process for quitting. We encourage smokers to be open with their health care providers about their struggles to quit. Providers can help them switch tactics to figure out the best strategy to help them quit for good,” Dr. Scheuermann concluded.

For more information:

COPD World News - Week of February 4, 2018

Researchers confirm link between flu and heart attack 

Toronto, ON - In the study published in the January 25 issue of the New England Journal of Medicine, the researchers found a significant association between acute respiratory infections, particularly influenza, and acute myocardial infarction. The risk may be higher for older adults, patients with influenza B infections, and patients experiencing their first heart attack. The researchers also found elevated risk – albeit not as high as for influenza – with infection from other respiratory viruses. “Our findings, combined with previous evidence that influenza vaccination reduces cardiovascular events and mortality, support international guidelines that advocate for influenza immunization in those at high risk of heart attacks,” says Kwong. The researchers looked at nearly 20,000 Ontario adult cases of laboratory-confirmed influenza infection from 2009 to 2014 and identified 332 patients who were hospitalized for a heart attack within one year of a laboratory-confirmed influenza diagnosis. “People at risk of heart disease should take precautions to prevent respiratory infections, and especially influenza, through measures including vaccinations and handwashing,” says Kwong. The researchers add that patients should not delay medical evaluation for heart symptoms particularly within the first week of an acute respiratory infection. The author block includes: Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, Katz K, Ko DT, McGeer AJ, McNally D, Richardson D, Rosella LC, Simor A, Smieja M, Zahariadis G, Gubbay JB. The article is titled, “Acute myocardial infarction after laboratory-confirmed influenza infection”

For more information:

COPD World News - Week of January 28, 2018

Smoking duration provides stronger risk estimate of COPD than pack-years    

London, UK – Researchers here stated that cigarette smoking is the strongest risk factor for COPD. Smoking burden is frequently measured in pack-years, but the relative contribution of cigarettes smoked per day versus duration towards the development of structural lung disease, airflow obstruction and functional outcomes is not known. The researchers analysed cross-sectional data from a large multicentre cohort (COPDGene) of current and former smokers. Primary outcome was airflow obstruction (FEV1/FVC); secondary outcomes included five additional measures of disease: FEV1, CT emphysema, CT gas trapping, functional capacity (6 min walk distance, 6MWD) and respiratory morbidity (St George’s Respiratory Questionnaire, SGRQ). Generalised linear models were estimated to compare the relative contribution of each smoking variable with the outcomes, after adjustment for age, race, sex, body mass index, CT scanner, centre, age of smoking onset and current smoking status. We also estimated adjusted means of each outcome by categories of pack-years and combined groups of categorised smoking duration and cigarettes/day, and estimated linear trends of adjusted means for each outcome by categorised cigarettes/day, smoking duration and pack-years. Results were based on 10,187 subjects. For FEV1/FVC, standardised beta coefficient for smoking duration was greater than for cigarettes/day and pack-years. After categorisation, there was a linear increase in adjusted means FEV1/FVC with increase in pack-years and duration over all ranges of smoking cigarettes/day but a relatively flat slope for cigarettes/day across all ranges of smoking duration. Strength of association of duration was similarly greater than pack-years for emphysema, gas trapping, FEV1, 6MWD and SGRQ. The researchers concluded that smoking duration alone provides stronger risk estimates of COPD than the composite index of pack-years. The study was recently published in the British Thoracic Society’s journal Thorax.

For more information:

COPD World News - Week of January 21, 2018

Respimat inhaler awarded Arthritis Foundation’s ease of use commendation  

Ridgefield, CT - The Arthritis Foundation has recently recognized Respimat by awarding the inhaler an ease of use commendation. “The Arthritis Foundation awards its Ease of Use Commendation when a product’s design or packaging has been proven to make taking medication easy and comfortable for people living with arthritis,” said Cindy McDaniel, Senior Vice President, Consumer Health, Arthritis Foundation. “To earn this Commendation, the Respimat inhaler went through a series of evaluations from experts and people living with arthritis.” The Respimat inhaler was designed to deliver the medication through a slow-moving mist, which gets medicine deep into patients’ lungs. The slow-moving mist of the Respimat inhaler provides patients with enough time to breathe in the medication. In addition, the Respimat inhaler operates independent of inspiratory effort, helping patients effectively breathe the medicine into their lungs without having to sharply inhale the medicine. As with all inhaled drugs, the actual amount of drug delivered to the lung may depend on patient factors, such as coordination between actuation of the inhaler and inspiration through the delivery system. The duration of inhalation should be at least as long as the spray duration (1.5 seconds). To earn the Ease of Use Commendation, the Respimat inhaler was independently tested by experts at the Intuitive Design Applied Research Institute(link is external) lab in Atlanta and evaluated by people with arthritis. “We are proud of our Respimat inhaler as being the first and only inhaler recognized by the Arthritis Foundation as easy-to-use for everyone,” said Jean-Michel Boers, president, Human Pharma, Boehringer Ingelheim Pharmaceuticals, Inc. “For nearly a century, we have been committed to advancing care for serious respiratory diseases, and the Respimat inhaler is an important achievement as part of this long-standing commitment.” Boehringer Ingelheim’s Respimat family of products includes four FDA-approved medicines for COPD as well as one for asthma.

For more information:

Genetic Lung Variants May Identify COPD Risk  

New York, NY - Genetic variations in the anatomy of the lungs could potentially identify smokers at high risk for developing chronic obstructive pulmonary disease (COPD), researchers reported. Inherited lung central airway branch variants were identified in about a quarter of the study population using CT scanning, and the most commonly seen variant was associated with higher COPD and chronic bronchitis prevalence in smokers and nonsmokers, according to Benjamin M. Smith, MD, of Columbia University Medical Center in New York City, and McGill University in Montreal, and colleagues. The second most common airway branch variant was associated with higher COPD risk among smokers, but not non-smokers they wrote in the Proceedings of the National Academy of Sciences. "The central airway tree develops early in life," Smith said. "We found that central airway branch variants, which are easily detected with standard clinical CT, were associated with higher odds of COPD later in life. These findings suggest that the central airway tree may be a useful biomarker to identify people at higher or lower COPD risk." James Kiley, MD, director of the division of lung diseases at the National Heart Lung and Blood Institute, noted that the findings raise interesting questions for researchers. "Understanding precisely why these genes influence the development of COPD may lead to entirely new and more effective ways of preventing or treating this disease," Kiley noted in a press statement. "This novel study suggests that a CT scan, which is widely available, can be used to measure airway structure and predict who is at higher risk for smoke-induced lung injury." Other than smoking risk, susceptibility to COPD is poorly understood. "Cigarette smoking is the major COPD risk factor, but COPD is not rare among those who have never smoked cigarettes and many smokers do not develop COPD," Smith's group wrote. "Furthermore, approximately half of older adults with COPD exhibit low lung function early in life. These observations suggest that host factors beyond smoking may contribute to COPD risk and may create opportunities for personalized disease prevention and treatment." Genome-wide association studies (GWAS) have identified several genes that regulate tracheobronchial tree formation in utero, which may influence susceptibility to COPD and other lung diseases, they noted. Smith's demonstrated that lower-lobe segmental airway branch variants were common among participants in the large Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study, which included both non-smokers and current and former smokers.

For more information:

COPD World News - Week of January 14, 2018

Hamilton hospitals over capacity as flu season surges

Hamilton, ON - Emergency rooms in Hamilton are over capacity, as local hospitals feel the strain of flu season spreading through the city. Health officials across the country are reporting higher than normal lab-confirmed cases of the flu. Hamilton has mostly dodged that bullet, local officials say, with numbers sitting in the mid-level range for what the city usually experiences around this time of year. The face of health-care cuts were illustrated as a grandmother dies and while no paramedics were available to help Flu activity in Canada 'high' and continuing to rise, latest public health numbers say. But even without a larger-than-normal spike, hospitals are still over capacity, says Ian Preyra, chief of emergency medicine at St. Joseph's Hamilton. St. Joes is currently 28 beds over capacity due to the surge. "When we're over capacity, it's not just a number. People really feel it," Preyra said. "It means those ambulances can't be offloaded, patients may wait longer, and patients who are admitted to hospital may wait to find a bed." As is the norm when hospitals are crowded, code zero ambulance events — which is when there is only one or fewer ambulances across the service's entire fleet available for a call — have spiked. There have been 16 code zeros in Hamilton already this month, only halfway through January. Code zero ambulance events have spiked in January during flu season, city statistics show. (CBC) Last year there were 21 code zero events in all of January, and that was the highest number for a single month in the whole year. The union representing local paramedics has long said code zeros are dangerous. Union officials say they're caused by a surge in call volumes for help, coupled with increasingly long wait times offloading patients in local hospitals. Hamilton Health Sciences is operating over capacity too, said spokesperson Lillian Badzioch in an email. "Our adult medical/surgical bed occupancy rate has been consistently over 105 per cent since October 2016 and was 114 per cent yesterday (Jan. 15)," she wrote. Emergency department physicians have also identified that there has been an increase in overall respiratory complaints and that overall volume has gone up, she said. In the first week of January there were 44 lab-confirmed cases of flu in Hamilton, according to the city. There were 19 the week before, in the last week of 2017. That's a middle-of-the-road situation for what Hamilton sees most years, said Dr. Ninh Tran, associate medical officer of health. "That will give us a sense as to if the trend is going up," Tran said. While Hamilton's numbers remain relatively steady, the number of people stricken by flu continues to rise across the country, with 15,572 laboratory-confirmed cases for the season to date.

For more information:

COPD World News - Week of January 7, 2018

Study suggests dietary antioxidants slow lung function decline  

Hamburg and Erfurt in Germany; Ipswich and Norwich in the UK; and Bergen in Norway - The relationship between lung function decline and dietary antioxidants over 10 years in adults from three European countries was investigated. Adults from three participating countries of the European Community Respiratory Health Survey (ECRHS) answered a questionnaire and underwent spirometry (forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC)), which were repeated 10 years later. Dietary intake was estimated at baseline with food frequency questionnaires (FFQ). Associations between annual lung function decline (mL) and diet were examined with multivariable analyses. A total of 680 individuals (baseline mean age 43.8±6.6 years) were included. A controlled increase in apple and banana intake was associated with a 3.59 mL·year−1 (95% CI 0.40, 7.68) and 3.69 mL·year−1 (95% CI 0.25, 7.14) slower decline in FEV1 and FVC, respectively. Tomato intake was also associated with a slower decline in FVC (4.5 mL·year−1; 95% CI 1.28, 8.02). Subgroup analyses showed that apple, banana and tomato intake were all associated with a slower decline in FVC in ex-smokers. Intake of fruits and tomatoes might delay lung function decline in adults, particularly in ex-smokers. One limitation of the study is that the researchers only had dietary assessments at baseline on one occasion for the three countries. They had to assume that diet remained relatively constant in adult life, and evidence for this exists. Investigations of the association between single nutrients and disease might not accurately reflect a specific dietary habit or dietary behaviour, as neither foods, nor nutrients are consumed in isolation. Information on nutrient supplementation was not collected, and we cannot rule out whether adjustment for this might have altered estimates. However, studies on nutrient supplementation and lung function have shown little evidence of an association. In conclusion, the study suggests that dietary factors might play a role in preserving ventilatory function in adults, by slowing down a decline in lung function. In particular, dietary antioxidants possibly contribute to restoration, following damage caused by exposure to smoking, among adults who have quit. The study was published in a recent edition of the European Respiratory Journal.

For more information: